Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Feb;95(2):555–563. doi: 10.1172/JCI117698

Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells.

L Cui 1, S Yoon 1, R F Schinazi 1, J P Sommadossi 1
PMCID: PMC295512  PMID: 7860738

Abstract

We have explored the mechanism(s) related to FIAU-induced liver toxicity, particularly focusing on its effect on mitochondrial function in a human hepatoma cell line-HepG2. The potential role of FMAU and FAU, metabolites detected in FIAU-treated patients were also ascertained. FIAU and FMAU inhibited cell growth and were effectively phosphorylated. A substantial increase in lactic acid production in medium of cells incubated with 1-10 microM FIAU or FMAU was consistent with mitochondrial dysfunction. Slot blot analysis demonstrated that a two week exposure to 10 microM FIAU or FMAU was not associated with a decrease in total mitochondrial (mt) DNA content. However, FIAU and FMAU were incorporated into nuclear and mtDNA and relative values suggest that both compounds incorporate at a much higher rate into mtDNA. Electron micrographs of cells incubated with 10 microM FIAU or FMAU revealed the presence of enlarged mitochondria with higher cristae density and lipid vesicles. In conclusion, these data suggest that despite the lack of inhibition of mtDNA content, incorporation of FIAU and FMAU into mtDNA of HepG2 cells leads to marked mitochondrial dysfunction as evidenced by disturbance in cellular energy metabolism and detection of micro- and macrovesicular steatosis.

Full text

PDF
555

Images in this article

559Image
on p.559
561Image
on p.561
562Image
on p.562
562Image
on p.562

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aden D. P., Fogel A., Plotkin S., Damjanov I., Knowles B. B. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 1979 Dec 6;282(5739):615–616. doi: 10.1038/282615a0. [DOI] [PubMed] [Google Scholar]
  2. Anderson S., Bankier A. T., Barrell B. G., de Bruijn M. H., Coulson A. R., Drouin J., Eperon I. C., Nierlich D. P., Roe B. A., Sanger F. Sequence and organization of the human mitochondrial genome. Nature. 1981 Apr 9;290(5806):457–465. doi: 10.1038/290457a0. [DOI] [PubMed] [Google Scholar]
  3. Chen C. H., Cheng Y. C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. J Biol Chem. 1989 Jul 15;264(20):11934–11937. [PubMed] [Google Scholar]
  4. Chen C. H., Cheng Y. C. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2',3'-dideoxycytidine. J Biol Chem. 1992 Feb 15;267(5):2856–2859. [PubMed] [Google Scholar]
  5. Chen C. H., Vazquez-Padua M., Cheng Y. C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol. 1991 May;39(5):625–628. [PubMed] [Google Scholar]
  6. Chen M. S., Amico L. A., Speelman D. J. Kinetics of the interaction of monophosphates of the antiviral nucleosides 2'-fluoro-1-beta-D-arabinofuranosylpyrimidine and (E)-5-(2-bromovinyl)-2'-deoxyuridine with thymidylate kinases from Vero cells and herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1984 Nov;26(5):778–780. doi: 10.1128/aac.26.5.778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chen M. S., Van Nostrand M., Oshana S. C. Quantitative determination of antiviral nucleoside analog in DNA. Anal Biochem. 1986 Aug 1;156(2):300–304. doi: 10.1016/0003-2697(86)90256-3. [DOI] [PubMed] [Google Scholar]
  8. Cheng Y. C., Dutschman G., Fox J. J., Watanabe K. A., Machida H. Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases. Antimicrob Agents Chemother. 1981 Sep;20(3):420–423. doi: 10.1128/aac.20.3.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chou T. C., Feinberg A., Grant A. J., Vidal P., Reichman U., Watanabe K. A., Fox J. J., Philips F. S. Pharmacological disposition and metabolic fate of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in mice and rats. Cancer Res. 1981 Sep;41(9 Pt 1):3336–3342. [PubMed] [Google Scholar]
  10. Clayton D. A. Replication of animal mitochondrial DNA. Cell. 1982 Apr;28(4):693–705. doi: 10.1016/0092-8674(82)90049-6. [DOI] [PubMed] [Google Scholar]
  11. Dalakas M. C., Illa I., Pezeshkpour G. H., Laukaitis J. P., Cohen B., Griffin J. L. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med. 1990 Apr 19;322(16):1098–1105. doi: 10.1056/NEJM199004193221602. [DOI] [PubMed] [Google Scholar]
  12. Darlington G. J., Kelly J. H., Buffone G. J. Growth and hepatospecific gene expression of human hepatoma cells in a defined medium. In Vitro Cell Dev Biol. 1987 May;23(5):349–354. doi: 10.1007/BF02620991. [DOI] [PubMed] [Google Scholar]
  13. Drew W. L., Miner R., King D. Antiviral activity of FIAU (1-[2'deoxy-2'-fluoro-1-beta-D-arabinofuranosyl]-5-iodo-uridine) on strains of cytomegalovirus sensitive and resistant to ganciclovir. J Infect Dis. 1991 Jun;163(6):1388–1389. doi: 10.1093/infdis/163.6.1388. [DOI] [PubMed] [Google Scholar]
  14. Faraj A., Fowler D. A., Bridges E. G., Sommadossi J. P. Effects of 2',3'-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis. Antimicrob Agents Chemother. 1994 May;38(5):924–930. doi: 10.1128/aac.38.5.924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Faulds D., Brogden R. N. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs. 1992 Jul;44(1):94–116. doi: 10.2165/00003495-199244010-00008. [DOI] [PubMed] [Google Scholar]
  16. Fourel I., Hantz O., Watanabe K. A., Jacquet C., Chomel B., Fox J. J., Trepo C. Inhibitory effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother. 1990 Mar;34(3):473–475. doi: 10.1128/aac.34.3.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Furman P. A., Davis M., Liotta D. C., Paff M., Frick L. W., Nelson D. J., Dornsife R. E., Wurster J. A., Wilson L. J., Fyfe J. A. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother. 1992 Dec;36(12):2686–2692. doi: 10.1128/aac.36.12.2686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Grant A. J., Feinberg A., Chou T. C., Watanabe K. A., Fox J. J., Philips F. S. Incorporation of metabolites of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine into deoxyribonucleic acid of neoplastic and normal mammalian tissues. Biochem Pharmacol. 1982 Mar 15;31(6):1103–1108. doi: 10.1016/0006-2952(82)90349-5. [DOI] [PubMed] [Google Scholar]
  19. Hoofnagle J. H., Shafritz D. A., Popper H. Chronic type B hepatitis and the "healthy" HBsAg carrier state. Hepatology. 1987 Jul-Aug;7(4):758–763. doi: 10.1002/hep.1840070424. [DOI] [PubMed] [Google Scholar]
  20. Krähenbühl S., Reichen J. Adaptation of mitochondrial metabolism in liver cirrhosis. Different strategies to maintain a vital function. Scand J Gastroenterol Suppl. 1992;193:90–96. doi: 10.3109/00365529209096012. [DOI] [PubMed] [Google Scholar]
  21. Philips F. S., Feinberg A., Chou T. C., Vidal P. M., Su T. L., Watanabe K. A., Fox J. J. Distribution, metabolism, and excretion of 1-(2-fluoro-2-deoxy-beta-D- arabinofuranosyl)thymine and 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5- iodocytosine. Cancer Res. 1983 Aug;43(8):3619–3627. [PubMed] [Google Scholar]
  22. Poulton J., Deadman M. E., Gardiner R. M. Duplications of mitochondrial DNA in mitochondrial myopathy. Lancet. 1989 Feb 4;1(8632):236–240. doi: 10.1016/s0140-6736(89)91256-7. [DOI] [PubMed] [Google Scholar]
  23. Sassa S., Sugita O., Galbraith R. A., Kappas A. Drug metabolism by the human hepatoma cell, Hep G2. Biochem Biophys Res Commun. 1987 Feb 27;143(1):52–57. doi: 10.1016/0006-291x(87)90628-0. [DOI] [PubMed] [Google Scholar]
  24. Schinazi R. F., Fox J. J., Watanabe K. A., Nahmias A. J. Activities of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2. Antimicrob Agents Chemother. 1986 Jan;29(1):77–84. doi: 10.1128/aac.29.1.77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Schinazi R. F., McMillan A., Cannon D., Mathis R., Lloyd R. M., Peck A., Sommadossi J. P., St Clair M., Wilson J., Furman P. A. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother. 1992 Nov;36(11):2423–2431. doi: 10.1128/aac.36.11.2423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Sells M. A., Zelent A. Z., Shvartsman M., Acs G. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol. 1988 Aug;62(8):2836–2844. doi: 10.1128/jvi.62.8.2836-2844.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Smith J. B., Smith L. Energy dependence of sodium-calcium exchange in vascular smooth muscle cells. Am J Physiol. 1990 Aug;259(2 Pt 1):C302–C309. doi: 10.1152/ajpcell.1990.259.2.C302. [DOI] [PubMed] [Google Scholar]
  28. Sommadossi J. P. Nucleoside analogs: similarities and differences. Clin Infect Dis. 1993 Feb;16 (Suppl 1):S7–15. doi: 10.1093/clinids/16.supplement_1.s7. [DOI] [PubMed] [Google Scholar]
  29. Stanley P. E., Williams S. G. Use of the liquid scintillation spectrometer for determining adenosine triphosphate by the luciferase enzyme. Anal Biochem. 1969 Jun;29(3):381–392. doi: 10.1016/0003-2697(69)90323-6. [DOI] [PubMed] [Google Scholar]
  30. Staschke K. A., Colacino J. M., Mabry T. E., Jones C. D. The in vitro anti-hepatitis B virus activity of FIAU [1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell. Antiviral Res. 1994 Jan;23(1):45–61. doi: 10.1016/0166-3542(94)90032-9. [DOI] [PubMed] [Google Scholar]
  31. Szmuness W. Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol. 1978;24:40–69. [PubMed] [Google Scholar]
  32. Watanabe K. A., Reichman U., Hirota K., Lopez C., Fox J. J. Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides. J Med Chem. 1979 Jan;22(1):21–24. doi: 10.1021/jm00187a005. [DOI] [PubMed] [Google Scholar]
  33. Welter C., Dooley S., Blin N. A rapid protocol for the purification of mitochondrial DNA suitable for studying restriction fragment length polymorphisms. Gene. 1989 Nov 15;83(1):169–172. doi: 10.1016/0378-1119(89)90415-0. [DOI] [PubMed] [Google Scholar]
  34. White E. L., Parker W. B., Macy L. J., Shaddix S. C., McCaleb G., Secrist J. A., 3rd, Vince R., Shannon W. M. Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases. Biochem Biophys Res Commun. 1989 Jun 15;161(2):393–398. doi: 10.1016/0006-291x(89)92611-9. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES